COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Interest is increasing in pooled sampling for SARS-CoV-2 surveillance testing. CMS addressed three primary questions in a recent FAQ.
Five points of interest to clinical laboratory leaders, gleaned from an over 8,000-word payer guidance document jointly developed by federal agencies.
This point-of-care test can potentially scale up to test millions, according to FDA Commissioner Stephen Hahn, MD.
Explanation of warnings issued to KBMO Diagnostics related to at-home COVID-19 testing.
Where to start when working on a laboratory developed test using next generation sequencing (NGS) technology for diagnosing SARS-CoV-2, according to Timothy Stenzel, MD, PhD.
Selected quotes from Jeffrey Shuren, MD, JD, Director of the Center for Devices and Radiological Health at the FDA on the June 16, 2020, updates to EUA templates.
Interest is increasing in pooled sampling for SARS-CoV-2 surveillance testing. CMS addressed three primary questions in a recent FAQ.
Five points of interest to clinical laboratory leaders, gleaned from an over 8,000-word payer guidance document jointly developed by federal agencies.
This point-of-care test can potentially scale up to test millions, according to FDA Commissioner Stephen Hahn, MD.
Explanation of warnings issued to KBMO Diagnostics related to at-home COVID-19 testing.
Where to start when working on a laboratory developed test using next generation sequencing (NGS) technology for diagnosing SARS-CoV-2, according to Timothy Stenzel, MD, PhD.
Selected quotes from Jeffrey Shuren, MD, JD, Director of the Center for Devices and Radiological Health at the FDA on the June 16, 2020, updates to EUA templates.
